Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma
| العنوان: | Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma |
|---|---|
| المؤلفون: | Xibin Qiu, Gungli Xiao, Hu Hao, Tongyu Lin, Yanqun Chen, Kin Iong Chan, Yabing Cao, Sao Chi Mak |
| المصدر: | BMC Cancer BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019) |
| بيانات النشر: | BioMed Central, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Cancer Research, B7-H1 Antigen, 0302 clinical medicine, Surgical oncology, Aged, 80 and over, Nasopharyngeal Carcinoma, biology, Chemoradiotherapy, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Immunohistochemistry, Progression-Free Survival, ErbB Receptors, Survival Rate, 030220 oncology & carcinogenesis, Cohort, Female, Research Article, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, lcsh:RC254-282, BRAF, 03 medical and health sciences, PD-L1, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, Clinical significance, In patient, Programmed death-ligand 1, neoplasms, Aged, Retrospective Studies, business.industry, Cancer, Nasopharyngeal Neoplasms, medicine.disease, 030104 developmental biology, Nasopharyngeal carcinoma, Mutation, biology.protein, business, Follow-Up Studies |
| الوصف: | Background The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study we investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients. Methods A retrospective review of 154 NPC patients form our previous study (BMC Cancer. 2013; 13:226) were conducted. Survival and prognostic impacts were analyzed based on PD-L1, BRAF and EGFR expression levels. Results One hundred fifty four patients were included in this study. PD-L1 expression was detected in 87.7% of patients; 14.3% had 1–5% PD-L1 expression, 47.4% had 5–49% expression while 26% had ≥50% expression Higher PD-L1 expression was significantly associated with shorter PFS and OS. The median PFS was 25 months (95% CI 15.7–34.3 months) and OS was 35 months (95% CI 22.60–47.4 months) for patients with PD-L1 expression ≥50%; both median PFS and OS were not yet reached for patients with PD-L1 expression P = 0.044). Conclusion Tumor PD-L1 expression and BRAF mutation are associated with poor outcomes in patients with NPC. This study was retrospectively registered in ClinicalTrials.gov (NCT03989297) on 2019-6-18. |
| اللغة: | English |
| تدمد: | 1471-2407 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298fa1bdfd781b78fb38e8e73939c498Test http://europepmc.org/articles/PMC6819586Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....298fa1bdfd781b78fb38e8e73939c498 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712407 |
|---|